PMID- 36660714
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230121
IS  - 2305-5839 (Print)
IS  - 2305-5847 (Electronic)
IS  - 2305-5839 (Linking)
VI  - 10
IP  - 24
DP  - 2022 Dec
TI  - Yishen Xiezhuo formula ameliorates the development of cisplatin-induced acute 
      kidney injury by attenuating renal tubular epithelial cell senescence.
PG  - 1392
LID - 10.21037/atm-22-5415 [doi]
LID - 1392
AB  - BACKGROUND: Although cisplatin (DDP) is an important clinical anti-tumor drug, 
      its use is limited by its nephrotoxicity. How to avoid the renal injury incurred 
      by platinum drugs and improve the clinical efficiency of platinum drugs use has 
      become an urgent clinical problem. Previous studies have verified that Chinese 
      medicine has definite effects on acute kidney injury (AKI). Yishen Xiezhuo 
      formula (YSXZ) is a traditional Chinese medicine (TCM) compound which is an 
      effective clinical drug for AKI, but its mechanism remains unclear. METHODS: In 
      our research, an AKI model was induced by DDP in human renal tubular epithelial 
      cell (HKC) lines in the in vitro study. The mechanism of the YSXZ on cell 
      senescence was analyzed by Cell Counting Kit-8 (CCK-8), senescence-associated 
      beta-galactosidase (SA-beta-Gal) staining, western blot, flow cytometry, and 
      enzyme-linked immunosorbent assay (ELISA). Network pharmacology was used to 
      analyze the role of YSXZ against AKI. RESULTS: Compared with the control group, 
      the cells in the DDP intervention group were significantly senescent. Compared 
      with DDP group, YSXZ decreased the number of SA-beta-Gal-positive senescence cells, 
      down regulated the expression of senescence-related proteins, reduced the release 
      of senescence-related secreted phenotypic factors, and reversed the phenomenon of 
      cell cycle S-phase arrest. Network pharmacology and experimental studies showed 
      that the mitogen-activated protein kinase (MAPK) signaling pathway played a 
      central role. CONCLUSIONS: Our present results suggested that YSXZ ameliorated 
      the development of DDP-induced AKI by attenuating renal tubular epithelial cell 
      (RTEC) senescence via alleviating the activation of MAPK pathway.
CI  - 2022 Annals of Translational Medicine. All rights reserved.
FAU - Zhang, Qiaoying
AU  - Zhang Q
AD  - Department of Nephrology, Integrated Hospital of Traditional Chinese Medicine, 
      Southern Medical University, Guangzhou, China.
FAU - Qi, Jieying
AU  - Qi J
AD  - Department of Nephrology, Integrated Hospital of Traditional Chinese Medicine, 
      Southern Medical University, Guangzhou, China.
FAU - Luo, Qin
AU  - Luo Q
AD  - Department of Nephrology, Integrated Hospital of Traditional Chinese Medicine, 
      Southern Medical University, Guangzhou, China.
FAU - Wu, Mengni
AU  - Wu M
AD  - Department of Nephrology, Integrated Hospital of Traditional Chinese Medicine, 
      Southern Medical University, Guangzhou, China.
FAU - Zhang, Lili
AU  - Zhang L
AD  - Department of Nephrology, Integrated Hospital of Traditional Chinese Medicine, 
      Southern Medical University, Guangzhou, China.
FAU - Qin, Linsen
AU  - Qin L
AD  - Department of Nephrology, Integrated Hospital of Traditional Chinese Medicine, 
      Southern Medical University, Guangzhou, China.
FAU - Nie, Xiaoli
AU  - Nie X
AD  - Department of Nephrology, Integrated Hospital of Traditional Chinese Medicine, 
      Southern Medical University, Guangzhou, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC9843381
OTO - NOTNLM
OT  - Yishen Xiezhuo formula (YSXZ)
OT  - acute kidney injury (AKI)
OT  - cell senescence
OT  - cisplatin (DDP)
OT  - network pharmacology
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://atm.amegroups.com/article/view/10.21037/atm-22-5415/coif). XN reports 
      that this work was supported by the National Natural Science Foundation of China 
      (No. 81774038) and the Natural Science Foundation of Guangdong Province (Nos. 
      2015A020213300 and 2021A1515011672). The other authors have no conflicts of 
      interest to declare.
EDAT- 2023/01/21 06:00
MHDA- 2023/01/21 06:01
PMCR- 2022/12/01
CRDT- 2023/01/20 02:16
PHST- 2022/09/30 00:00 [received]
PHST- 2022/12/20 00:00 [accepted]
PHST- 2023/01/20 02:16 [entrez]
PHST- 2023/01/21 06:00 [pubmed]
PHST- 2023/01/21 06:01 [medline]
PHST- 2022/12/01 00:00 [pmc-release]
AID - atm-10-24-1392 [pii]
AID - 10.21037/atm-22-5415 [doi]
PST - ppublish
SO  - Ann Transl Med. 2022 Dec;10(24):1392. doi: 10.21037/atm-22-5415.